Phathom Pharmaceuticals (PHAT) Stock Trends and Sentiment $8.78 -0.31 (-3.41%) (As of 11/15/2024 ET) Add Compare Share Share Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Media Mentions Over Time8 Last Week 4 Current Week -50.0%View Trending Media Stocks MarketBeat New Followers Over Time0 Last Week 2 Current Week +200.0%View Trending Stocks on MarketBeat MarketBeat Searches Over Time1 Last Week 3 Current Week +200.0% Page Views Over Time562 Last Week 879 Current Week +56.4% WallStreetBets Posts Over Time0 Last Week 2 Current Week +200.0%View Trending WallStreetBets Stocks Recieve Phathom Pharmaceuticals News and Ratings via Email Sign-up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address PHAT Social Media Mentions Related Companies and Tools Related Companies ORIC Pharmaceuticals Stock Sentiment Nkarta Stock Sentiment Karyopharm Therapeutics Stock Sentiment BioXcel Therapeutics Stock Sentiment Innoviva Stock Sentiment Supernus Pharmaceuticals Stock Sentiment Akero Therapeutics Stock Sentiment NewAmsterdam Pharma Stock Sentiment Scholar Rock Stock Sentiment Recursion Pharmaceuticals Stock Sentiment Trends Tools Trending StocksTrending Media MentionsHigh Media Sentiment StocksTrending WallStreetBets StocksLive News Feed This page (NASDAQ:PHAT) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
